COMMUNIQUÉS West-GlobeNewswire

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

20/05/2024 - 22:05

Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open label extension (OLE) study initially evaluating 25 mg; Larimar plans to dose [...]

TELA Bio Appoints Greg Firestone as Chief Commercial Officer

20/05/2024 - 22:03

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the [...]

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

20/05/2024 - 22:01

WALTHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

20/05/2024 - 22:01

- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - - First patient with liver metastases treated in a feasibility and safety study of [...]

Nurix Therapeutics Announces Board Chair Transition

20/05/2024 - 22:00

David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO, May 20, 2024 (GLOBE [...]

“NASDAQ JAPAN IR EVENT” to Be Held at Nasdaq MarketSite on June 20, 2024

20/05/2024 - 21:00

Discover the appeal of Japanese companies listed in the U.S. NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM”, the [...]

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

20/05/2024 - 20:30

KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD) [...]

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

20/05/2024 - 20:15

Dupixent ® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced [...]

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

20/05/2024 - 20:15

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive [...]

Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO

20/05/2024 - 20:15

Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent ® dans le traitement de la BPCO Les résultats de l’étude NOTUS confirment [...]

Nature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® Therapy

20/05/2024 - 17:35

ARC Therapy™ shown to be safe and effective in global pivotal trial* 90% of participants improved either strength or function of upper limbs* Improvement demonstrated in participants up to 34 years post-injury* 87% of [...]

U.S. Patent and Trademark Office Grants US Patent # 11,975,112 for “Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine”

20/05/2024 - 16:36

Olanzapine (ZYPREXA ® ) is an antipsychotic medication used to treat schizophrenia and bipolar disorder that is commonly used as anti-nausea off label medication. Olanzapine has been investigated for use as an [...]

Grin Garners Recognition From MedTech Breakthrough With “Best New Orthodontics Technology Solution”

20/05/2024 - 16:00

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies LOS ANGELES, May 20, 2024 (GLOBE NEWSWIRE) -- MedTech Breakthrough , an independent [...]

American Addiction Centers Names Greenhouse Treatment Center a Veterans Center of Excellence

20/05/2024 - 15:50

GRAND PRAIRIE, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- American Addiction Centers (AAC) has recognized Greenhouse Treatment Center as a Veterans Center of Excellence, highlighting its commitment to providing high- [...]

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

20/05/2024 - 15:15

OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor [...]

Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

20/05/2024 - 15:00

-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy with the potential [...]

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

20/05/2024 - 15:00

Granted Indian Patent for its MyoVista® Wavelet Technology Southlake, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), [...]

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

20/05/2024 - 14:45

Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score and total lung [...]

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

20/05/2024 - 14:30

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the [...]